Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Statin use and serum cholesterol reduction have been proposed as preventions for dementia and mild cognitive impairment (MCI). Methods: 1604 and 1345 eligible participants from the Baltimore Longitudinal Study of Aging (BLSA) were followed after age 50 for a median time of around 25 years, to examine the incidence of dementia (n=259) and MCI (n=138), respectively. Statin use (ever-use and time-dependent use), total cholesterol levels (TC; first visit and time-dependent), TC change trajectory from first visit and high-density lipoprotein (HDL-C):TC ratio (first visit and time-dependent) were the main exposures of interest. Cox proportional hazards models were used. Results: Participants with incident dementia had a higher first-visit TC compared with participants who remained free of dementia and MCI, while first-visit TC was higher among statin ever-users compared with never-users (age-unadjusted associations). Statin users had a two- to threefold lower risk of developing dementia (HR=0.41; 95% CI 0.18 to 0.92), but not MCI, when considering time-dependent ‘statin use’ with propensity score model adjustment. This association remained significant independently of serum cholesterol exposures. An elevated first-visit TC was associated with reduced MCI risk (upper quartile (Q 4) vs Q 1: HR=0.51; 95% CI 0.29 to 0.90). Compared with the lowest quartile (Q 1: 0.00–0.19), HDL-C:TC (time-dependent) in (Q 2: 0.19–0.24) was associated with reduced MCI risk (HR=0.58; 95% CI 0.34 to 0.98). Among men only, TC decline from first visit was significantly associated with increased dementia risk (HR=4.21; 95% CI 1.28 to 13.85). Conclusions: Statins may have multifactorial effects on dementia but not MCI risk. Future interventions may be warranted, and research should focus on optimal serum TC, HDL-C:TC ratio and TC change trajectories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000) · Neurology · doi:10.1212/wnl.54.11.2072 · Cited by 472
Self-citationHaag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393
Cited by
Deckers, K., van Boxtel, M. P. J., Schiepers, O. J. G., de Vugt, M., Muñoz Sánchez, J. L., Anstey, K. J., Brayne, C., Dartigues, J.-F., Engedal, K., Kivipelto, M., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4245 · Cited by 534
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Anstey, K. J., Ashby-Mitchell, K., & Peters, R. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160826 · Cited by 360
“However, studies publishing on midlife lacked clear information on the age range of the sample at baseline and the distribution of the sample within midlife and late-life [12, 21].”
BackgroundResultInfluentialStatins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
“…disease, diabetes mellitus, depression, use of tricyclic antidepressants or selective serotonin reuptake inhibitors, body mass index; Beydoun et al, 2011: age, sex, race, education, cardiovascular disease, cerebrovascular disease, hypertension, diabetes mellitus, atrial…”
BackgroundInfluentialHuckans, M., Hutson, L., Twamley, E., Jak, A., Kaye, J., & Storzbach, D. (2013) · Neuropsychology Review · doi:10.1007/s11065-013-9230-9 · Cited by 201
“2012) Disease risk factors Cardiovascular disease, high cholesterol, high blood pressure (Barnes et al. 2006; Beydoun et al. 2011; Goldstein et al. 2013; Hai et al. 2012; Luck et al. 2010a, b; Sachdev et al. 2012) Metabolic and endocrine diseases, diabetes mellitus, thyroid dysfunction (Cheng et al.”
BackgroundOlmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
Dyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
Statins, cognition, and dementia-systematic review and methodological commentary
Power, M. C., Weuve, J., Sharrett, A. R., Blacker, D., & Gottesman, R. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.35 · Cited by 150
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Butterfield, D. A., Barone, E., & Mancuso, C. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.007 · Cited by 80
“Early clinical data based on cohort and case-control studies, demonstrated that statins reduced the risk to develop dementia, including Alzheimer disease (AD), and this protective effect was maintained over a 6 year follow-up period [60–67].”
ResultStatins use and risk of dementia: A dose–response meta analysis
Zhang, X., Wen, J., & Zhang, Z. (2018) · Medicine · doi:10.1097/md.0000000000011304 · Cited by 78
Emulating a target trial of statin use and risk of dementia using cohort data
Caniglia, E. C., Rojas-Saunero, L. P., Hilal, S., Licher, S., Logan, R., Stricker, B., Ikram, M. A., & Swanson, S. A. (2020) · Neurology · doi:10.1212/wnl.0000000000010433 · Cited by 56
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease
Kim, M.-Y., Jung, M., Noh, Y., Shin, S., Hong, C. H., Lee, S., & Jung, Y.-S. (2020) · Biomedicines · doi:10.3390/biomedicines8020030 · Cited by 23
Du, Y., Yu, Z., Li, C., Zhang, Y., & Xu, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1473796 · Cited by 13
Metadata
- Authors
- Beydoun, M. A., Beason-Held, L. L., Kitner-Triolo, M. H., Beydoun, H. A., Ferrucci, L., Resnick, S. M., & Zonderman, A. B.
- Venue
- Journal of Epidemiology and Community Health
- Publisher
- BMJ
- Published
- 2010-09-14
- Volume
- 65
- Issue
- 11
- Pages
- 949-957
- ISSN
- 0141-7681 (ISSN-L)
- 0143-005X
- 1470-2738
- OpenAlex
- W2161990655
- Cited by
- 113
- References
- 5
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.